[ABCG1 transporter gene expression in peripheral blood mononuclear cells of patients with atherosclerosis]

Tsitologiia
|December 17, 2014
PubMed

Insights

Reduced ABCG1 gene expression in macrophages is linked to atherosclerosis. Lower ABCG1 mRNA levels in monocytes correlate with artery occlusion, indicating ABCG1

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Atherosclerosis Research

Background:

  • Macrophage cholesterol accumulation is central to atherosclerosis.
  • ABCG1 transporter facilitates cholesterol efflux to HDL, impacting foam cell formation.

Purpose of the Study:

  • Investigate the role of ABCG1 in human atherosclerosis development.
  • Examine ABCG1 gene expression in atherosclerosis patients versus controls.

Main Methods:

  • Real-time PCR and Western blotting to quantify ABCG1 mRNA and protein.
  • Analysis of gene expression in leukocytes, monocytes, and macrophages.

Main Results:

  • Monocyte ABCG1 mRNA inversely correlated with artery occlusion rate (r = -0.45, P = 0.016).
  • Significantly reduced ABCG1 mRNA and protein in macrophages of coronary artery stenosis patients.
  • Lower monocyte ABCG1 mRNA in patients with 100% artery occlusion.

Conclusions:

  • Decreased ABCG1 gene expression in macrophages is associated with atherosclerosis.
  • ABCG1 plays a significant role in the pathogenesis of atherosclerosis.

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
168
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
74
ABC Transporters: Exporter01:31

ABC Transporters: Exporter

ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
7.3K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
104